Rockville, Maryland’s Fina Biosolutions recently was awarded an SBIR grant to develop a genetically detoxified tetanus toxin as a carrier protein for conjugate vaccines. The NIAID funded grant is for $289,000 and…
Development of FinaBio’s CRM197, EcoCRM® and Ready-to-ConjugateTM carrier proteins. Presented April 15, 2020 to the Canadian Glycomics Network About the Canadian Glycomics Network In 2015, the Canadian glycomics research community mobilized to…
PATH (path.org), an organization promoting health in low income countries, has published an article on their smaller partners, including Fina Biosolutions. FinaBio has worked with PATH on conjugate vaccines for…
Fina Biosolutions LLC of Rockville, MD has signed a development agreement for two conjugate vaccines with the Chinese Institute of Medical Biology (Kunming), part of the Chinese Academy of Medicine.…
BioTalk summary here. Listen now on Google Play bit.ly/2CzdnA9, iTunes, apple.co/2Arsfze, TuneIn bit.ly/2M60Wmx.
The Johns Hopkins Medical & Surgical Association will present Fina Biosolutions founder and scientific director, Andrew Lees,their “Distinguished Alumni Award”. The award will be presented at theirannual Reunion & Alumni…
For Immediate Release: Fina Biosolutions’ Licensee Successfully Completes a Phase 3 Study and Enters World Health Organization (WHO) Registration for Pneumosil® Serum Institute of India completes a Phase 3 clinical trial…
Last month, the Maryland Tech Council stopped by Fina Biosolutions, where they met with Founder, CEO and Chief Scientific Officer, Dr. Andrew Lees. Dr. Lees was a gracious host, giving…
Fina Biosolutions licenses CRM197 vaccine component to PATH for use in low-income countries November 15, 2018 06:00 AM Eastern Standard Time ROCKVILLE, Md. - Fina Biosolutions LLC announced today it has reached agreement…
Proprietary method of producing CRM197 will be used to develop affordable vaccines for children and adults in developing nations Rockville, MD., September 27, 2018–Fina Biosolutions announces that the United States…